Skip to main content
Search
Search
Quick Search anywhere
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Skip main navigationClose Drawer MenuOpen Drawer Menu
JACC Journals › JACC › Archives › Vol. 81 No. 18
Previous
Next

Heart Failure With Preserved Ejection Fraction: JACC Scientific StatementGET ACCESS

JACC Scientific Statement

J Am Coll Cardiol. 2023 May, 81 (18) 1810–1834
Sections

Central Illustration

Abstract

The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) continue to rise in tandem with the increasing age and burdens of obesity, sedentariness, and cardiometabolic disorders. Despite recent advances in the understanding of its pathophysiological effects on the heart, lungs, and extracardiac tissues, and introduction of new, easily implemented approaches to diagnosis, HFpEF remains under-recognized in everyday practice. This under-recognition presents an even greater concern given the recent identification of highly effective pharmacologic-based and lifestyle-based treatments that can improve clinical status and reduce morbidity and mortality. HFpEF is a heterogenous syndrome and recent studies have suggested an important role for careful, pathophysiological-based phenotyping to improve patient characterization and to better individualize treatment. In this JACC Scientific Statement, we provide an in-depth and updated examination of the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF.

Highlights

•

HFpEF is an increasingly common cause of exercise intolerance linked to obesity and sedentary behavior.

•

Despite advances in understanding of pathophysiological mechanisms, diagnosis, and treatment, HFpEF remains under-recognized.

•

Further research is needed to characterize HFpEF phenotypes to promote individualized management and to improve outcomes.

References

  • 1. Pfeffer M.A., Shah A.M., Borlaug B.A. "Heart failure with preserved ejection fraction in perspective". Circ Res . 2019;124:1598-1617.

    CrossrefMedlineGoogle Scholar

  • 2. Anker S.D., Butler J., Filippatos G., et al. "Empagliflozin in heart failure with a preserved ejection fraction". N Engl J Med . 2021;385:1451-1461.

    CrossrefMedlineGoogle Scholar

  • 3. Solomon S.D., McMurray J.J.V., Claggett B., et al. "Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction". N Engl J Med . 2022;387:1089-1098.

    CrossrefMedlineGoogle Scholar

  • 4. Bozkurt B., Coats A.J.S., Tsutsui H., et al. "Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by Canadian Heart Failure Society, Heart Failure Association of India, the Cardiac Society of Australia and New Zealand, and the Chinese Heart Failure Association". Eur J Heart Fail . 2021;23:352-380.

    CrossrefMedlineGoogle Scholar

  • 5. Verbrugge F.H., Omote K., Reddy Y.N.V., Sorimachi H., Obokata M., Borlaug B.A. "Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality". Eur Heart J . 2022;43:1941-1951.

    CrossrefMedlineGoogle Scholar

  • 6. Shah S.J. "BNP: biomarker not perfect in heart failure with preserved ejection fraction". Eur Heart J . 2022;43:1952-1954.

    CrossrefMedlineGoogle Scholar

  • 7. Obokata M., Reddy Y.N.V., Melenovsky V., Sorimachi H., Jarolim P., Borlaug B.A. "Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity". Eur J Heart Fail . 2022;24:353-361.

    CrossrefMedlineGoogle Scholar

  • 8. Borlaug B.A., Jensen M.D., Kitzman D.W., Lam C.S.P., Obokata M., Rider O.J. "Obesity and heart failure with preserved ejection fraction: new insights and pathophysiologic targets". Cardiovasc Res . 2023;118:3434-3450.

    CrossrefMedlineGoogle Scholar

  • 9. Gerber Y., Weston S.A., Redfield M.M., et al. "A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010". JAMA Intern Med . 2015;175:996-1004.

    CrossrefMedlineGoogle Scholar

  • 10. Tsao C.W., Lyass A., Enserro D., et al. "Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction". J Am Coll Cardiol HF . 2018;6:678-685.

    Google Scholar

  • 11. Bhambhani V., Kizer J.R., Lima J.A.C., et al. "Predictors and outcomes of heart failure with mid-range ejection fraction". Eur J Heart Fail . 2018;20:651-659.

    CrossrefMedlineGoogle Scholar

  • 12. Steinberg B.A., Zhao X., Heidenreich P.A., et al. "Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes". Circulation . 2012;126:65-75.

    CrossrefMedlineGoogle Scholar

  • 13. Clark K.A.A., Reinhardt S.W., Chouairi F., et al. "Trends in heart failure hospitalizations in the US from 2008 to 2018". J Card Fail . 2022;28:171-180.

    CrossrefMedlineGoogle Scholar

  • 14. Pandey A., Omar W., Ayers C., et al. "Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction". Circulation . 2018;137:1814-1823.

    CrossrefMedlineGoogle Scholar

  • 15. Ho J.E., Lyass A., Lee D.S., et al. "Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction". Circ Heart Fail . 2013;6:279-286.

    CrossrefMedlineGoogle Scholar

  • 16. Dunlay S.M., Roger V.L., Redfield M.M. "Epidemiology of heart failure with preserved ejection fraction". Nat Rev Cardiol . 2017;14:591-602.

    CrossrefMedlineGoogle Scholar

  • 17. Chang P.P., Wruck L.M., Shahar E., et al. "Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC Study Community Surveillance". Circulation . 2018;138:12-24.

    CrossrefMedlineGoogle Scholar

  • 18. Ho J.E., Enserro D., Brouwers F.P., et al. "Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes". Circ Heart Fail . 2016;9:e003116. https://doi.org/10.1161/CIRCHEARTFAILURE.115.003116.

    CrossrefMedlineGoogle Scholar

  • 19. Savji N., Meijers W.C., Bartz T.M., et al. "The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF". J Am Coll Cardiol HF . 2018;6:701-709.

    Google Scholar

  • 20. Pandey A., LaMonte M., Klein L., et al. "Relationship between physical activity, body mass index, and risk of heart failure". J Am Coll Cardiol . 2017;69:1129-1142.

    View ArticleGoogle Scholar

  • 21. Koepp K.E., Reddy Y.N.V., Obokata M., et al. "Identification of patients with preclinical heart failure with preserved ejection fraction using the H2FPEF score". Nat Cardiovasc Res . 2022;1:59-66.

    CrossrefMedlineGoogle Scholar

  • 22. Selvaraj S., Myhre P.L., Vaduganathan M., et al. "Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community". J Am Coll Cardiol HF . 2020;8:640-653.

    Google Scholar

  • 23. Shah K.S., Xu H., Matsouaka R.A., et al. "Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes". J Am Coll Cardiol . 2017;70:2476-2486.

    View ArticleGoogle Scholar

  • 24. Vaduganathan M., Patel R.B., Michel A., et al. "Mode of death in heart failure with preserved ejection fraction". J Am Coll Cardiol . 2017;69:556-569.

    View ArticleGoogle Scholar

  • 25. Jha A.K., Ojha C.P., Krishnan A.M., Paul T.K. "Thirty-day readmission in patients with heart failure with preserved ejection fraction: Insights from the nationwide readmission database". World J Cardiol . 2022;14:473-482.

    CrossrefMedlineGoogle Scholar

  • 26. Desai A.S., Vaduganathan M., Cleland J.G., et al. "Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF trial". Circ Heart Fail . 2021;14:e008597.

    CrossrefGoogle Scholar

  • 27. Lewis E.F., Claggett B., Shah A.M., et al. "Racial differences in characteristics and outcomes of patients with heart failure and preserved ejection fraction in the treatment of preserved cardiac function heart failure trial". Circ Heart Fail . 2018;11:e004457.

    CrossrefGoogle Scholar

  • 28. Wang X., Vaduganathan M., Claggett B.L., et al. "Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER". Circulation . 2023;147:624-634.

    CrossrefMedlineGoogle Scholar

  • 29. Kawaguchi M., Hay I., Fetics B., Kass D.A. "Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations". Circulation . 2003;107:714-720.

    CrossrefMedlineGoogle Scholar

  • 30. Borlaug B.A., Melenovsky V., Russell S.D., et al. "Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction". Circulation . 2006;114:2138-2147.

    CrossrefMedlineGoogle Scholar

  • 31. Zile M.R., Baicu C.F., Gaasch W.H. "Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle". N Engl J Med . 2004;350:1953-1959.

    CrossrefMedlineGoogle Scholar

  • 32. Lam C.S., Roger V.L., Rodeheffer R.J., et al. "Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota". Circulation . 2007;115:1982-1990.

    CrossrefMedlineGoogle Scholar

  • 33. Ng A.C.T., Delgado V., Borlaug B.A., Bax J.J. "Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging". Nat Rev Cardiol . 2021;18:291-304.

    CrossrefMedlineGoogle Scholar

  • 34. Paulus W.J., Tschope C. "A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation". J Am Coll Cardiol . 2013;62:263-271.

    View ArticleGoogle Scholar

  • 35. Schiattarella G.G., Rodolico D., Hill J.A. "Metabolic inflammation in heart failure with preserved ejection fraction". Cardiovasc Res . 2021;117:423-434.

    CrossrefMedlineGoogle Scholar

  • 36. Pandey A., Shah S.J., Butler J., et al. "Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC STATE-OF-THE-ART REVIEW". J Am Coll Cardiol . 2021;78:1166-1187.

    View ArticleGoogle Scholar

  • 37. Paulus W.J., Zile M.R. "From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited". Circ Res . 2021;128:1451-1467.

    CrossrefMedlineGoogle Scholar

  • 38. Hahn V.S., Yanek L.R., Vaishnav J., et al. "Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis". J Am Coll Cardiol HF . 2020;8:712-724.

    Google Scholar

  • 39. Rosch S., Kresoja K.P., Besler C., et al. "Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction". Circulation . 2022;146:506-518.

    CrossrefMedlineGoogle Scholar

  • 40. van Heerebeek L., Borbély A., Niessen H.W.M., et al. "Myocardial structure and function differ in systolic and diastolic heart failure". Circulation . 2006;113:1966-1973.

    CrossrefMedlineGoogle Scholar

  • 41. van Heerebeek L., Hamdani N., Handoko M.L., et al. "Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension". Circulation . 2008;117:43-51.

    CrossrefMedlineGoogle Scholar

  • 42. van Heerebeek L., Hamdani N., Falcão-Pires I., et al. "Low myocardial protein kinase g activity in heart failure with preserved ejection fraction". Circulation . 2012;126:830-839.

    CrossrefMedlineGoogle Scholar

  • 43. Zile M.R., Baicu C.F., Ikonomidis J.S., et al. "Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin". Circulation . 2015;131:1247-1259.

    CrossrefMedlineGoogle Scholar

  • 44. Obokata M., Reddy Y.N., Pislaru S.V., Melenovsky V., Borlaug B.A. "Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction". Circulation . 2017;136:6-19.

    CrossrefMedlineGoogle Scholar

  • 45. Borlaug B.A., Reddy Y.N.V. "The role of the pericardium in heart failure: implications for pathophysiology and treatment". J Am Coll Cardiol HF . 2019;7:574-585.

    Google Scholar

  • 46. Wohlfahrt P., Redfield M.M., Lopez-Jimenez F., et al. "Impact of general and central adiposity on ventricular-arterial aging in women and men". J Am Coll Cardiol HF . 2014;2:489-499.

    Google Scholar

  • 47. Feldschuh J., Enson Y. "Prediction of the normal blood volume. Relation of blood volume to body habitus". Circulation . 1977;56:605-612.

    CrossrefMedlineGoogle Scholar

  • 48. Miller W.L., Borlaug B.A. "Impact of obesity on volume status in patients with ambulatory chronic heart failure". J Card Fail . 2020;26:112-117.

    CrossrefMedlineGoogle Scholar

  • 49. Sorimachi H., Burkhoff D., Verbrugge F.H., et al. "Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction". Eur J Heart Fail . 2021;23:1648-1658.

    CrossrefMedlineGoogle Scholar

  • 50. Aslam M.I., Hahn V.S., Jani V., Hsu S., Sharma K., Kass D.A. "Reduced right ventricular sarcomere contractility in heart failure with preserved ejection fraction and severe obesity". Circulation . 2021;143:965-967.

    CrossrefMedlineGoogle Scholar

  • 51. Peterson L.R., Herrero P., Schechtman K.B., et al. "Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women". Circulation . 2004;109:2191-2196.

    CrossrefMedlineGoogle Scholar

  • 52. Burrage M.K., Hundertmark M., Valkovič L., et al. "Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction". Circulation . 2021;144:1664-1678.

    CrossrefMedlineGoogle Scholar

  • 53. Rayner J.J., Peterzan M.A., Watson W.D., et al. "Myocardial energetics in obesity: enhanced ATP delivery through creatine kinase with blunted stress response". Circulation . 2020;141:1152-1163.

    CrossrefMedlineGoogle Scholar

  • 54. Hahn V.S., Knutsdottir H., Luo X., et al. "Myocardial gene expression signatures in human heart failure with preserved ejection fraction". Circulation . 2021;143:120-134.

    CrossrefMedlineGoogle Scholar

  • 55. Koepp K.E., Obokata M., Reddy Y.N.V., Olson T.P., Borlaug B.A. "Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction". J Am Coll Cardiol HF . 2020;8:657-666.

    Google Scholar

  • 56. Reddy Y.N.V., Lewis G.D., Shah S.J., et al. "Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study". Mayo Clin Proc . 2019;94:1199-1209.

    CrossrefMedlineGoogle Scholar

  • 57. Redfield M.M., Anstrom K.J., Levine J.A., et al. "Isosorbide mononitrate in heart failure with preserved ejection fraction". N Engl J Med . 2015;373:2314-2324.

    CrossrefMedlineGoogle Scholar

  • 58. Borlaug B.A., Anstrom K.J., Lewis G.D., et al. "Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial". JAMA . 2018;320:1764-1773.

    CrossrefMedlineGoogle Scholar

  • 59. Udelson J.E., Lewis G.D., Shah S.J., et al. "Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial". JAMA . 2020;324:1522-1531.

    CrossrefMedlineGoogle Scholar

  • 60. Armstrong P.W., Lam C.S.P., Anstrom K.J., et al. "Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial". JAMA . 2020;324:1512-1521.

    CrossrefMedlineGoogle Scholar

  • 61. Sanders-van Wijk S., van Empel V., Davarzani N., et al. "Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction". Eur J Heart Fail . 2015;17:1006-1014.

    CrossrefMedlineGoogle Scholar

  • 62. Kalogeropoulos A., Georgiopoulou V., Psaty B.M., et al. "Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study". J Am Coll Cardiol . 2010;55:2129-2137.

    View ArticleGoogle Scholar

  • 63. Markousis-Mavrogenis G., Tromp J., Ouwerkerk W., et al. "The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study". Eur J Heart Fail . 2019;21:965-973.

    CrossrefMedlineGoogle Scholar

  • 64. Sabbah M.S., Fayyaz A.U., de Denus S., et al. "Obese-inflammatory phenotypes in heart failure with preserved ejection fraction". Circ Heart Fail . 2020;13:e006414.

    CrossrefGoogle Scholar

  • 65. Shah S.J., Lam C.S.P., Svedlund S., et al. "Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF". Eur Heart J . 2018;39:3439-3450.

    CrossrefMedlineGoogle Scholar

  • 66. Yang J.H., Obokata M., Reddy Y.N.V., Redfield M.R., Lerman A., Borlaug B.A. "Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction". Eur J Heart Fail . 2020;22:432-441.

    CrossrefMedlineGoogle Scholar

  • 67. Rush C.J., Berry C., Oldroyd K.G., et al. "Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction". JAMA Cardiol . 2021;6:1130-1143.

    CrossrefMedlineGoogle Scholar

  • 68. Sanders-van Wijk S., Tromp J., Beussink-Nelson L., et al. "Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study". Circulation . 2020;142:2029-2044.

    CrossrefMedlineGoogle Scholar

  • 69. Mohammed S.F., Hussain S., Mirzoyev S.A., Edwards W.D., Maleszewski J.J., Redfield M.M. "Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction". Circulation . 2015;131:550-559.

    CrossrefMedlineGoogle Scholar

  • 70. Patel R.B., Colangelo L.A., Bielinski S.J., et al. "Circulating vascular cell adhesion molecule-1 and incident heart failure: the Multi-Ethnic Study of Atherosclerosis (MESA)". J Am Heart Assoc . 2020;9:e019390.

    CrossrefGoogle Scholar

  • 71. Patel R.B., Colangelo L.A., Reiner A.P., et al. "Cellular adhesion molecules in young adulthood and cardiac function in later life". J Am Coll Cardiol . 2020;75:2156-2165.

    View ArticleGoogle Scholar

  • 72. Schiattarella G.G., Altamirano F., Tong D., et al. "Nitrosative stress drives heart failure with preserved ejection fraction". Nature . 2019;568:351-356.

    CrossrefMedlineGoogle Scholar

  • 73. Rao V.N., Zhao D., Allison M.A., et al. "Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis)". J Am Coll Cardiol HF . 2018;6:999-1007.

    Google Scholar

  • 74. Sorimachi H., Omote K., Omar M., et al. "Sex and central obesity in heart failure with preserved ejection fraction". Eur J Heart Fail . 2022;24:1359-1370.

    CrossrefMedlineGoogle Scholar

  • 75. Sorimachi H., Obokata M., Takahashi N., et al. "Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction". Eur Heart J . 2021;42:1595-1605.

    CrossrefMedlineGoogle Scholar

  • 76. Packer M. "Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis". Circulation . 2022;146:1383-1405.

    CrossrefMedlineGoogle Scholar

  • 77. Borlaug B.A., Jaber W.A., Ommen S.R., Lam C.S.P., Redfield M.M., Nishimura R.A. "Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction". Heart . 2011;97:964-969.

    CrossrefMedlineGoogle Scholar

  • 78. Melenovsky V., Hwang S.-J., Redfield M.M., Zakeri R., Lin G., Borlaug B.A. "Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction". Circ Heart Fail . 2015;8:295-303.

    CrossrefMedlineGoogle Scholar

  • 79. Reddy Y.N.V., Obokata M., Verbrugge F.H., Lin G., Borlaug B.A. "Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation". J Am Coll Cardiol . 2020;76:1051-1064.

    View ArticleGoogle Scholar

  • 80. Freed B.H., Daruwalla V., Cheng J.Y., et al. "Prognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strain". Circ Cardiovasc Imag . 2016;9:e003754. https://doi.org/10.1161/CIRCIMAGING.115.003754.

    CrossrefMedlineGoogle Scholar

  • 81. Reddy Y.N.V., Obokata M., Egbe A., et al. "Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction". Eur J Heart Fail . 2019;21:891-900.

    CrossrefMedlineGoogle Scholar

  • 82. Telles F., Nanayakkara S., Evans S., et al. "Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction". Eur J Heart Fail . 2019;21:495-505.

    CrossrefMedlineGoogle Scholar

  • 83. Backhaus S.J., Lange T., George E.F., et al. "Exercise stress real-time cardiac magnetic resonance imaging for noninvasive characterization of heart failure with preserved ejection fraction: the HFpEF-Stress trial". Circulation . 2021;143:1484-1498.

    CrossrefMedlineGoogle Scholar

  • 84. Verbrugge F.H., Guazzi M., Testani J.M., Borlaug B.A. "Altered hemodynamics and end-organ damage in heart failure: impact on the lung and kidney". Circulation . 2020;142:998-1012.

    CrossrefMedlineGoogle Scholar

  • 85. Lam C.S., Roger V.L., Rodeheffer R.J., Borlaug B.A., Enders F.T., Redfield M.M. "Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study". J Am Coll Cardiol . 2009;53:1119-1126.

    View ArticleGoogle Scholar

  • 86. Omote K., Verbrugge F.H., Sorimachi H., et al. "Central hemodynamic abnormalities and outcome in patients with unexplained dyspnea". Eur J Heart Fail . 2023;25:185-196.

    CrossrefMedlineGoogle Scholar

  • 87. Vanderpool R.R., Saul M., Nouraie M., Gladwin M.T., Simon M.A. "Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction". JAMA Cardiol . 2018;3:298-306.

    CrossrefMedlineGoogle Scholar

  • 88. Fayyaz A.U., Edwards W.D., Maleszewski J.J., et al. "Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction". Circulation . 2018;137:1796-1810.

    CrossrefMedlineGoogle Scholar

  • 89. Omote K., Sorimachi H., Obokata M., et al. "Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications". Eur Heart J . 2022;43:3417-3431.

    CrossrefMedlineGoogle Scholar

  • 90. Melenovsky V., Hwang S.J., Lin G., Redfield M.M., Borlaug B.A. "Right heart dysfunction in heart failure with preserved ejection fraction". Eur Heart J . 2014;35:3452-3462.

    CrossrefMedlineGoogle Scholar

  • 91. Obokata M., Reddy Y.N.V., Melenovsky V., Pislaru S., Borlaug B.A. "Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction". Eur Heart J . 2019;40:689-697.

    CrossrefMedlineGoogle Scholar

  • 92. Borlaug B.A., Blair J., Bergmann M.W., et al. "Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure". Circulation . 2022;145:1592-1604.

    CrossrefMedlineGoogle Scholar

  • 93. Ho J.E., Zern E.K., Lau E.S., et al. "Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort". J Am Coll Cardiol . 2020;75:17-26.

    View ArticleGoogle Scholar

  • 94. Borlaug B.A., Olson T.P., Lam C.S.P., et al. "Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction". J Am Coll Cardiol . 2010;56:845-854.

    View ArticleGoogle Scholar

  • 95. Sorimachi H., Verbrugge F.H., Omote K., et al. "Longitudinal evolution of cardiac dysfunction in heart failure and preserved ejection fraction with normal natriuretic peptide levels". Circulation . 2022;146:500-502.

    CrossrefMedlineGoogle Scholar

  • 96. Lau E.S., Panah L.G., Zern E.K., et al. "Arterial stiffness and vascular load in HFpEF: differences among women and men". J Card Fail . 2022;28:202-211.

    CrossrefMedlineGoogle Scholar

  • 97. Reddy Y.N.V., Andersen M.J., Obokata M., et al. "Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction". J Am Coll Cardiol . 2017;70:136-148.

    View ArticleGoogle Scholar

  • 98. Kitzman D.W., Nicklas B., Kraus W.E., et al. "Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction". Am J Physiol Heart Circ Physiol . 2014;306:H1364-1370.

    CrossrefMedlineGoogle Scholar

  • 99. Houstis N.E., Eisman A.S., Pappagianopoulos P.P., et al. "Exercise intolerance in heart failure with preserved ejection fraction: diagnosing and ranking its causes using personalized O2 pathway analysis". Circulation . 2018;137:148-161.

    CrossrefMedlineGoogle Scholar

  • 100. Olson T.P., Johnson B.D., Borlaug B.A. "Impaired pulmonary diffusion in heart failure with preserved ejection fraction". J Am Coll Cardiol HF . 2016;4:490-498.

    Google Scholar

  • 101. Haykowsky M.J., Brubaker P.H., John J.M., Stewart K.P., Morgan T.M., Kitzman D.W. "Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction". J Am Coll Cardiol . 2011;58:265-274.

    View ArticleGoogle Scholar

  • 102. Sarma S., Stoller D., Hendrix J., et al. "Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction". Circ Heart Fail . 2020;13:e006331.

    CrossrefMedlineGoogle Scholar

  • 103. Fudim M., Kaye D.M., Borlaug B.A., et al. "Venous tone and stressed blood volume in heart failure: JACC review topic of the week". J Am Coll Cardiol . 2022;79:1858-1869.

    View ArticleGoogle Scholar

  • 104. Shah S.J., Kitzman D.W., Borlaug B.A., et al. "Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap". Circulation . 2016;134:73-90.

    CrossrefMedlineGoogle Scholar

  • 105. Sorimachi H., Omote K., Borlaug B.A. "Clinical phenogroups in heart failure with preserved ejection fraction". Heart Fail Clin . 2021;17:483-498.

    CrossrefMedlineGoogle Scholar

  • 106. Ho J.E., Redfield M.M., Lewis G.D., Paulus W.J., Lam C.S.P. "Deliberating the diagnostic dilemma of heart failure with preserved ejection fraction". Circulation . 2020;142:1770-1780.

    CrossrefMedlineGoogle Scholar

  • 107. Senni M., Caravita S., Paulus W.J. "Do existing definitions identify subgroup phenotypes or reflect the natural history of heart failure with preserved ejection fraction?"Circulation . 2019;140:366-369.

    CrossrefMedlineGoogle Scholar

  • 108. Peters A.E., Tromp J., Shah S.J., et al. "Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions". Cardiovasc Res . 2023;118:3403-3415.

    CrossrefMedlineGoogle Scholar

  • 109. Shah S.J., Katz D.H., Selvaraj S., et al. "Phenomapping for novel classification of heart failure with preserved ejection fraction". Circulation . 2015;131:269-279.

    CrossrefMedlineGoogle Scholar

  • 110. Ahmad F.S., Luo Y., Wehbe R.M., Thomas J.D., Shah S.J. "Advances in machine learning approaches to heart failure with preserved ejection fraction". Heart Fail Clin . 2022;18:287-300.

    CrossrefMedlineGoogle Scholar

  • 111. Shah S.J., Butler J., Shah S.H., Kamphaus T.N., Sachdev V. "Accelerating therapeutic discoveries for heart failure: a new public-private partnership". Nat Rev Drug Discov . 2022;21:781-782.

    CrossrefMedlineGoogle Scholar

  • 112. Borlaug B.A. "Evaluation and management of heart failure with preserved ejection fraction". Nat Rev Cardiol . 2020;17:559-573.

    CrossrefMedlineGoogle Scholar

  • 113. Jering K., Claggett B., Redfield M.M., et al. "Burden of heart failure signs and symptoms, prognosis, and response to therapy: the PARAGON-HF trial". J Am Coll Cardiol HF . 2021;9:386-397.

    Google Scholar

  • 114. Anjan V.Y., Loftus T.M., Burke M.A., et al. "Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction". Am J Cardiol . 2012;110:870-876.

    CrossrefMedlineGoogle Scholar

  • 115. Obokata M., Reddy Y.N.V., Borlaug B.A. "Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods". J Am Coll Cardiol Img . 2020;13:245-257.

    View ArticleGoogle Scholar

  • 116. Obokata M., Kane G.C., Reddy Y.N., Olson T.P., Melenovsky V., Borlaug B.A. "Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study". Circulation . 2017;135:825-838.

    CrossrefMedlineGoogle Scholar

  • 117. Reddy Y.N.V., Carter R.E., Obokata M., Redfield M.M., Borlaug B.A. "A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction". Circulation . 2018;138:861-870.

    CrossrefMedlineGoogle Scholar

  • 118. Pieske B., Tschöpe C., de Boer R.A., et al. "How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)". Eur Heart J . 2019;40:3297-3317.

    CrossrefMedlineGoogle Scholar

  • 119. Omote K., Hsu S., Borlaug B.A. "Hemodynamic assessment in heart failure with preserved ejection fraction". Cardiol Clin . 2022;40:459-472.

    CrossrefMedlineGoogle Scholar

  • 120. Eisman A.S., Shah R.V., Dhakal B.P., et al. "Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure". Circ Heart Fail . 2018;11:e004750.

    CrossrefMedlineGoogle Scholar

  • 121. Reddy Y.N.V., Kaye D.M., Handoko M.L., et al. "Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea". JAMA Cardiol . 2022;7:891-899.

    CrossrefMedlineGoogle Scholar

  • 122. D'Alto M., Badesch D., Bossone E., et al. "A fluid challenge test for the diagnosis of occult heart failure". Chest . 2021;159:791-797.

    CrossrefMedlineGoogle Scholar

  • 123. van de Bovenkamp A.A., Wijkstra N., Oosterveer F.P.T., et al. "The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction". Circ Heart Fail . 2022;15:e008935.

    CrossrefGoogle Scholar

  • 124. Andersen M.J., Olson T.P., Melenovsky V., Kane G.C., Borlaug B.A. "Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure". Circ Heart Fail . 2015;8:41-48.

    CrossrefMedlineGoogle Scholar

  • 125. Maeder M.T., Thompson B.R., Brunner-La Rocca H.P., Kaye D.M. "Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction". J Am Coll Cardiol . 2010;56:855-863.

    View ArticleGoogle Scholar

  • 126. Heidenreich P.A., Bozkurt B., Aguilar D., et al. "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol . 2022;79:e263-e421.

    View ArticleGoogle Scholar

  • 127. Zakeri R., Chamberlain A.M., Roger V.L., Redfield M.M. "Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study". Circulation . 2013;128:1085-1093.

    CrossrefMedlineGoogle Scholar

  • 128. Reddy Y.N.V., Borlaug B.A., Gersh B.J. "Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction". Circulation . 2022;146:339-357.

    CrossrefMedlineGoogle Scholar

  • 129. Kitzman D.W., Brubaker P., Morgan T., et al. "Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial". JAMA . 2016;315:36-46.

    CrossrefMedlineGoogle Scholar

  • 130. Sorimachi H., Obokata M., Omote K., et al. "Long-term changes in cardiac structure and function following bariatric surgery". J Am Coll Cardiol . 2022;80:1501-1512.

    View ArticleGoogle Scholar

  • 131. Reddy Y.N.V., Anantha-Narayanan M., Obokata M., et al. "Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis". J Am Coll Cardiol HF . 2019;7:678-687.

    Google Scholar

  • 132. Hwang S.J., Melenovsky V., Borlaug B.A. "Implications of coronary artery disease in heart failure with preserved ejection fraction". J Am Coll Cardiol . 2014;63:2817-2827.

    View ArticleGoogle Scholar

  • 133. Jackson A.M., Rørth R., Liu J., et al. "Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction". Eur J Heart Fail . 2022;24:497-509.

    CrossrefMedlineGoogle Scholar

  • 134. Nassif M.E., Windsor S.L., Borlaug B.A., et al. "The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial". Nat Med . 2021;27:1954-1960.

    CrossrefMedlineGoogle Scholar

  • 135. Jhund P.S., Kondo T., Butt J.H., et al. "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER". Nat Med . 2022;28:1956-1964.

    CrossrefMedlineGoogle Scholar

  • 136. Pitt B., et al. "Spironolactone for heart failure with preserved ejection fraction". N Engl J Med . 2014;370:1383-1392.

    CrossrefMedlineGoogle Scholar

  • 137. Pfeffer M.A., Pfeffer M.A., Assmann S.F., et al. "Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial". Circulation . 2015;131:34-42.

    CrossrefMedlineGoogle Scholar

  • 138. Solomon S.D., McMurray J.J.V., Anand I.S., et al. "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction". N Engl J Med . 2019;381:1609-1620.

    CrossrefMedlineGoogle Scholar

  • 139. Pieske B., Wachter R., Shah S.J., et al. "Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial". JAMA . 2021;326:1919-1929.

    CrossrefMedlineGoogle Scholar

  • 140. Pandey A., Parashar A., Kumbhani D., et al. "Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials". Circ Heart Fail . 2015;8:33-40.

    CrossrefMedlineGoogle Scholar

  • 141. Mueller S., Winzer E.B., Duvinage A., et al. "Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial". JAMA . 2021;325:542-551.

    CrossrefMedlineGoogle Scholar

  • 142. Adamson P.B., Abraham W.T., Bourge R.C., et al. "Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction". Circ Heart Fail . 2014;7:935-944.

    CrossrefMedlineGoogle Scholar

  • 143. Reddy Y.N.V., Koepp K.E., Carter R., et al. "Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial". JAMA . 2023;329:801-809.

    CrossrefMedlineGoogle Scholar

  • 144. Shah S.J., Borlaug B.A., Chung E.S., et al. "Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial". Lancet . 2022;399:1130-1140.

    CrossrefMedlineGoogle Scholar

  • 145. Borlaug B.A., Schaff H.V., Pochettino A., et al. "Pericardiotomy enhances left ventricular diastolic reserve with volume loading in humans". Circulation . 2018;138:2295-2297.

    CrossrefMedlineGoogle Scholar

  • 146. Jain C.C., Pedrotty D., Araoz P.A., et al. "Sustained improvement in diastolic reserve following percutaneous pericardiotomy in a porcine model of heart failure with preserved ejection fraction". Circ Heart Fail . 2021;14:e007530.

    CrossrefGoogle Scholar

  • 147. Fudim M., Fail P.S., Litwin S.E., et al. "Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort". Eur J Heart Fail . 2022;24:1410-1414.

    CrossrefMedlineGoogle Scholar

  • 148. Borlaug B.A., Redfield M.M. "Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum". Circulation . 2011;123:2006-2013.discussion 2014.

    CrossrefMedlineGoogle Scholar

  • 149. Lewis G.A., Dodd S., Clayton D., et al. "Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial". Nat Med . 2021;27:1477-1482.

    CrossrefMedlineGoogle Scholar

  • 150. Borlaug B.A., Maleszewski J.J. "The heavy heart of HFpEF". Eur Heart J . 2020;41:3447.

    CrossrefMedlineGoogle Scholar

  • 151. Hicks K.A., Mahaffey K.W., Mehran R., et al. "2017 cardiovascular and stroke endpoint definitions for clinical trials". J Am Coll Cardiol . 2018;71:1021-1034.

    View ArticleGoogle Scholar

  • 152. Cunningham J.W., Singh P., Reeder C. "Natural language processing for adjudication of heart failure in the electronic health record". J Am Coll Cardiol HF . 2023. Mar 5;S2213-1779(23)00098-7.

    View ArticleGoogle Scholar

  • 153. Brubaker P.H., Nicklas B.J., Houston D.K., et al. "A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction". Circ Heart Fail . 2023;16:2: e010161.

    MedlineGoogle Scholar